Novation contracts Amersham for nuclear medicine products

TriMed Staff | | Health Imaging | Practice Management
Amersham Health has received a three-year contract from Novation for its nuclear medicine radiopharmaceutical and related products.

 The pact is effective Jan. 1, 2004 through Dec. 31, 2006.

 The Buckinghamshire, United Kingdom company will provide the group purchasing company with products, such as its Myoview kit for the preparation of Technetium Tc99m and Tetrofosmin injection for myocardial perfusion.

 Novation is the supply company of VHA Inc., based in Irving, Texas, and University HealthSystem Consortium (UHC), which operates from Oakbrook, Ill.

TriMed Staff

Related Content

MRI accident has prompted the company that installed the scanner to issue a safety warning
Newly launched report feature provides patients with a visual aid to their imaging
Center for Devices and Radiological Health hit with federal job cuts
Overview of the regulatory landscape of AI in radiology
Concerns about private equity's growing influence in radiology
'Ad hoc' shifts and radiology 'maestros': How one department addressed its workflow hiccups

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.